Patient reported outcome measures among patients with vulvar cancer at various stages of treatment, recurrence, and survivorship.

Abstract:

OBJECTIVE:Our goal was to pragmatically describe patient reported outcomes (PROs) in a typical clinic population of vulvar cancer patients, as prior studies of vulvar cancer PROs have examined clinical trial participants. METHODS:A prospective PRO program was implemented in the Gynecologic Oncology clinic of a tertiary academic institution in January 2018. Vulvar cancer patients through September 2019 were administered the European Organization for the Research and Treatment of Cancer Quality of life Questionnaire, the Patient Reported Outcome Measurement Information System Instrumental and Emotional Support Scales, and the Functional Assessment of Cancer Therapy-Vulvar questionnaire. Binary logistic regressions were performed to determine adjusted odds ratios for adverse responses to individual questions by insurance, stage, age, time since diagnosis, recurrence, radiation, and surgical radicality. RESULTS:Seventy vulvar cancer patients responded to PROs (85.4% response rate). Seventy-one percent were > 1 year since diagnosis, 61.4% had stage I disease, and 28.6% recurred. Publicly insured women had less support and worse quality of life (QOL, aOR 4.15, 95% CI 1.00-17.32, p = 0.05). Women who recurred noted more interference with social activities (aOR 4.45, 95% CI 1.28-15.41, p = 0.019) and poorer QOL (aOR 5.22 95% CI 1.51-18.10, p = 0.009). There were no major differences by surgical radicality. Those >1 year since diagnosis experienced less worry (aOR 0.17, 95% CI 0.04-0.63, p = 0.008). CONCLUSIONS:Surgical radicality does not affect symptoms or QOL in vulvar cancer patients, whereas insurance, recurrence, and time since diagnosis do. This data can improve counseling and awareness of patient characteristics that would benefit from social services referral.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Alimena S,Sullivan MW,Philp L,Dorney K,Hubbell H,Del Carmen MG,Goodman A,Bregar A,Growdon WB,Eisenhauer EL,Sisodia RC

doi

10.1016/j.ygyno.2020.10.022

subject

Has Abstract

pub_date

2021-01-01 00:00:00

pages

252-259

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(20)34044-0

journal_volume

160

pub_type

杂志文章
  • Maximizing the diversity of participants in a phase II clinical trial of optical technologies to detect cervical neoplasia.

    abstract:INTRODUCTION:We compare the racial and ethnic demographics of our participants with the populations where our clinics are located (Texas and British Columbia) and investigate the reasons cited for participation. METHODS:We compared the distribution of participants by race/ethnicity to numbers from the 2000 United Stat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2007.07.063

    authors: Pham B,Earle N,Rabel K,Follen M,Scheurer ME

    更新日期:2007-10-01 00:00:00

  • Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate.

    abstract::The steroid receptor content of the primary endometrial cancer of 22 patients who were treated for recurrent or advanced disease has been measured and correlated with response to medroxyprogesterone acetate. No patient with a progesterone receptor (PR)-negative tumor responded and only 2 patients with PR-positive tumo...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90269-0

    authors: Quinn MA,Cauchi M,Fortune D

    更新日期:1985-07-01 00:00:00

  • Endometrial carcinoma: transvaginal ultrasonography prediction of depth of myometrial invasion.

    abstract::Myometrial invasion greater than 33% negatively affects the prognosis of endometrial carcinoma. Since the endometrium is readily differentiated from myometrium via high-resolution transvaginal sonography (TVS), this prospective study was undertaken to evaluate the efficacy of TVS in determining the depth of myometrial...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(91)90023-x

    authors: Sahakian V,Syrop C,Turner D

    更新日期:1991-12-01 00:00:00

  • Overall survival after pelvic exenteration for gynecologic malignancy.

    abstract:BACKGROUND:Five-Year survival after pelvic exenteration for gynecologic malignancies has been reported as high as 60%. The objective of this study was to determine overall survival (OS) after pelvic exenteration and evaluate factors impacting outcome. METHODS:A retrospective review of all women who underwent pelvic ex...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.06.034

    authors: Westin SN,Rallapalli V,Fellman B,Urbauer DL,Pal N,Frumovitz MM,Ramondetta LM,Bodurka DC,Ramirez PT,Soliman PT

    更新日期:2014-09-01 00:00:00

  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.

    abstract:OBJECTIVE:ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance. We comprehensively evaluated this gene and flanking regions for an association with clinical outcome in epithelial ovarian cancer (EOC). METHODS:The best candidates from fine-mapping analysis of 2...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.07.107

    authors: Johnatty SE,Beesley J,Gao B,Chen X,Lu Y,Law MH,Henderson MJ,Russell AJ,Hedditch EL,Emmanuel C,Fereday S,Webb PM,Australian Ovarian Cancer Study Group.,Goode EL,Vierkant RA,Fridley BL,Cunningham JM,Fasching PA,Beckmann

    更新日期:2013-10-01 00:00:00

  • Advanced endometrial cancer detected at 7 months after childbirth.

    abstract::It is very rare to find endometrial cancers arising within a short period following childbirth, presumably because pregnancy has a protective effect against endometrial cancer mediated by elevated secretion of progesterone. We present the case of a 30-year-old Japanese woman with stage IIIC endometrial cancer that was...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1996.4556

    authors: Kodama J,Yoshinouchi M,Miyagi Y,Kobashi Y,Kamimura S,Okuda H,Kudo T

    更新日期:1997-03-01 00:00:00

  • Isolated abdominal wound recurrence of an endometrial adenocarcinoma confined to a polyp.

    abstract::An unusual case of Stage IB moderately well-differentiated endometrial adenocarcinoma that was confined to a polyp and recurred only in the abdominal wound is presented. Eighteen months following complete excision, local electron beam therapy, and the institution of hormonal therapy, the patient is alive and without o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90089-2

    authors: Barter JF,Hatch KD,Orr JW Jr,Shingleton HM

    更新日期:1986-11-01 00:00:00

  • Second primary malignancy in endometrial carcinoma patients.

    abstract::An epidemiologic study of multiple primary malignant neoplasms in endometrial cancer patients in Israel is presented. During the 7-year period of the study, 104 patients (10.3%) out of 1007 patients diagnosed as having endometrial cancer had another primary cancer. There was a significant difference in the incidence o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90005-8

    authors: Schwartz Z,Ohel G,Birkenfeld A,Anteby SO,Schenker JG

    更新日期:1985-09-01 00:00:00

  • Placental site trophoblastic tumor: outcome of five cases including fertility preserving management.

    abstract:INTRODUCTION:Placental site trophoblastic tumor (PSTT) is a rare variant of gestational trophoblastic disease that has been re-described during the 1970s. MATERIALS AND METHODS:The patients' age at presentation, presenting symptoms, description of last pregnancy, treatment, and outcome were analyzed in five patients d...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.08.049

    authors: Machtinger R,Gotlieb WH,Korach J,Fridman E,Apter S,Goldenberg M,Ben-Baruch G

    更新日期:2005-01-01 00:00:00

  • Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.

    abstract:OBJECTIVES:MDM2 is an important negative regulator of the p53 tumor suppressor protein. A naturally occurring T/G single nucleotide polymorphism (SNP) in the MDM2 gene promoter, SNP309, causes an increase in MDM2 protein levels and impairment of p53 tumor suppressor activity. SNP309 occurs at a relatively high frequenc...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.10.008

    authors: Walsh CS,Miller CW,Karlan BY,Koeffler HP

    更新日期:2007-03-01 00:00:00

  • p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.

    abstract::Uterine papillary serous carcinoma (UPSC) is an uncommon but aggressive type of endometrial cancer associated with rapid progression of disease and poor prognosis. We investigated 23 cases of UPSC. p53 expression was studied in archival paraffin-embedded tissue by immunohistochemistry. Eleven tumors (47.8%) showed p53...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5113

    authors: Bancher-Todesca D,Gitsch G,Williams KE,Kohlberger P,Neunteufel W,Obermair A,Heinze G,Breitenecker G,Hacker NF

    更新日期:1998-10-01 00:00:00

  • Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.

    abstract:OBJECTIVE:The aim of this study was to assess the long-term effect of gonadotropin-releasing hormone analogues (GnRH-a) in combination with high-dose progestogens in the treatment of atypical endometrial hyperplasia in selected surgical high-risk patients and in women desiring reproductive potential. We hypothesized th...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1998.5322

    authors: Pérez-Medina T,Bajo J,Folgueira G,Haya J,Ortega P

    更新日期:1999-05-01 00:00:00

  • Preoperative pathologic findings associated with residual disease at radical hysterectomy in women with stage IA2 cervical cancer.

    abstract:OBJECTIVE:To correlate findings on pathologic examination of loop electroexcisional procedure (LEEP) or cone biopsy specimens with residual disease in radical hysterectomy specimens in patients with stage IA2 cervical cancer to determine whether a subset of such patients may be eligible for conservative, fertility-spar...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.09.011

    authors: Suri A,Frumovitz M,Milam MR,dos Reis R,Ramirez PT

    更新日期:2009-01-01 00:00:00

  • A cervical teratoma with invasive squamous cell carcinoma in an HIV-infected patient: a case report.

    abstract::HIV infection among women is increasing in the United States. Since January 1993, cervical cancer has been considered an AIDS-defining illness. We report a rare case of squamous cell carcinoma arising in a teratoma of the uterine cervix in an HIV-infected patient. This patient was treated with a radical hysterectomy, ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1996.0076

    authors: Bell MC,Schmidt-Grimminger DC,Connor MG,Alvarez RD

    更新日期:1996-03-01 00:00:00

  • Gemcitabine in cervical cancer.

    abstract:OBJECTIVE:Recurrent and advanced cervical cancers are associated with high mortality and a lack of effective treatment options, especially for women who are poor candidates for surgery or radiation therapy. The broad clinical effectiveness and low toxicity of gemcitabine in other human malignancies suggest that it migh...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0090-8258(03)00338-x

    authors: Mutch DG,Bloss JD

    更新日期:2003-08-01 00:00:00

  • A phase II study of leuprolide in advanced/recurrent endometrial cancer.

    abstract::In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study. Patients were included if there was clinical or radiological documentation of bidimensionally measurabl...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.1996.4544

    authors: Covens A,Thomas G,Shaw P,Ackerman I,Osborne R,Lukka H,Carey M,Franssen E,Roche K

    更新日期:1997-01-01 00:00:00

  • PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma.

    abstract::Twenty-six drug-resistant choriocarcinoma patients were treated with a PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin), supplemented by radiotherapy or surgery, from January 1988 to June 1992. A total of 80.8% of the patients had received at least four drugs, and 69.2% had received six or more cycles of...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1037

    authors: Chen LP,Cai SM,Fan JX,Li ZT

    更新日期:1995-02-01 00:00:00

  • An unusual case of secondary fibrosarcoma after treatment for breast cancer.

    abstract:BACKGROUND:Post-irradiation breast sarcoma is a rare and highly aggressive tumor, associated with poor prognosis. However, the mean latent periods reported for postradiation sarcomas after treatment of breast cancer ranges from 5 to 10 years. CASE:We present a rare case of fibrosarcoma of the axilla, diagnosed 23 mont...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2006.07.014

    authors: Plotti F,Di Donato V,Zullo MA,Angioli R,Panici PB

    更新日期:2006-12-01 00:00:00

  • Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis.

    abstract:BACKGROUND:An epigenetic approach to explaining endometrial carcinogenesis necessitates good understanding of Ras association domain family 1 isoform A (RASSF1A) promoter methylation data from primary studies. AIMS:Differential magnitude of reported associations between RASSF1A promoter methylation and endometrial can...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ygyno.2017.06.017

    authors: Pabalan N,Kunjantarachot A,Ruangpratheep C,Jarjanazi H,Christofolini DM,Barbosa CP,Bianco B

    更新日期:2017-09-01 00:00:00

  • A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.

    abstract:OBJECTIVE:To determine if there is an advantage to combination chemotherapy and radiation for optimally resected stage IIIC endometrial cancer (EC). METHODS:A multicenter retrospective analysis of patients with EC from 1991 to 2008 was conducted. Inclusion criteria were lymph node assessment and optimally resected dis...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2012.10.010

    authors: Secord AA,Geller MA,Broadwater G,Holloway R,Shuler K,Dao NY,Gehrig PA,O'Malley DM,Finkler N,Havrilesky LJ

    更新日期:2013-01-01 00:00:00

  • Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

    abstract:BACKGROUND:One of the most active chemotherapy combinations in advanced or recurrent cervical cancer is cisplatin-paclitaxel. However, this palliative regimen is associated with significant toxicity. Carboplatin-paclitaxel is thus an attractive option. METHODS:Patients with advanced or recurrent carcinoma of the cervi...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.03.037

    authors: Tinker AV,Bhagat K,Swenerton KD,Hoskins PJ

    更新日期:2005-07-01 00:00:00

  • Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.

    abstract:OBJECTIVE:Early-stage epithelial ovarian cancer represents a prognostically heterogenous group. We studied prognostic factors in patients treated with adjuvant paclitaxel/carboplatin chemotherapy. METHODS:Data was extracted from 147 patients with FIGO stage IA/IB, grade 2/3 or stage IC/IIA (any grade) who underwent pr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.06.033

    authors: Bamias A,Karadimou A,Soupos N,Sotiropoulou M,Zagouri F,Haidopoulos D,Thomakos N,Rodolakis A,Antsaklis A,Dimopoulos MA

    更新日期:2011-10-01 00:00:00

  • Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.

    abstract:OBJECTIVE:Using data from a case-control study of endometrial cancer, we investigated the relationship between the progestin and estrogen potency in combination oral contraceptives (OCs) and the risk of developing endometrial cancer. METHODS:Subjects included 434 endometrial cancer cases and 2,557 controls identified ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.03.046

    authors: Maxwell GL,Schildkraut JM,Calingaert B,Risinger JI,Dainty L,Marchbanks PA,Berchuck A,Barrett JC,Rodriguez GC

    更新日期:2006-11-01 00:00:00

  • Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis.

    abstract:OBJECTIVE:This study explores patterns of lifestyle change and whether more threatening illness perceptions are associated with lifestyle changes post-treatment for smoking, alcohol consumption and Body Mass Index (BMI) among gynecological cancer patients. METHODS:In total, 395 cancer patients (N=221 endometrial; N=17...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.ygyno.2017.02.037

    authors: van Broekhoven MECL,de Rooij BH,Pijnenborg JMA,Vos MC,Boll D,Kruitwagen RFPM,van de Poll-Franse LV,Ezendam NPM

    更新日期:2017-05-01 00:00:00

  • An improved radioimmunoassay for human ovarian tumor antigen NB/70K.

    abstract::An improved assay for the measurement of human ovarian tumor antigen NB/70K (triton NB/70K assay) has been developed. This assay makes the accurate and reproducible estimation of serum NB/70K possible. Freezing and thawing of serum up to three times or refrigeration of diluted serum up to 7 days does not significantly...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90160-4

    authors: Knauf S,Taillon-Miller P

    更新日期:1984-09-01 00:00:00

  • Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.

    abstract::The purpose of this study was to evaluate the biological significance of Ki67 antigen expression in serous ovarian tumors, through the analysis of MIB 1 monoclonal antibody reactivity in cystoadenomas, borderline tumors, and invasive cystoadenocarcinomas; the correlation between this index of cell proliferation and cl...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1026

    authors: Garzetti GG,Ciavattini A,Goteri G,De Nictolis M,Stramazzotti D,Lucarini G,Biagini G

    更新日期:1995-02-01 00:00:00

  • Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.

    abstract:OBJECTIVE:Preoperative identification of cervical stromal invasion in endometrial carcinoma is important to select patients for primary radical hysterectomy. The objective of this prospective implementation study was to assess if introduction of magnetic resonance imaging (MRI) in addition to the standardly applied end...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.05.009

    authors: Haldorsen IS,Berg A,Werner HM,Magnussen IJ,Helland H,Salvesen OO,Trovik J,Salvesen HB

    更新日期:2012-09-01 00:00:00

  • Risk factors for prolonged hospitalization after gynecologic laparoscopic surgery.

    abstract:OBJECTIVE:To determine perioperative risk factors for prolonged hospitalization after gynecologic laparoscopic surgery. METHODS:Data on patients who underwent gynecologic laparoscopic surgery at a single academic institution from January 2000 to January 2009 were evaluated. Patient demographics, clinical history, intr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.05.037

    authors: Zand B,Frumovitz M,Jofre MF,Nick AM,Dos Reis R,Munsell MF,Sangi-Haghpeykar H,Levenback C,Soliman PT,Schmeler KM,Ramirez PT

    更新日期:2012-09-01 00:00:00

  • Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors.

    abstract:OBJECTIVE:The aberrant expression of hepatocyte growth factor and its receptor c-Met are associated with aggressive disease and poor prognosis in a variety of human malignancies including ovarian cancer (OC). Specificity protein (Sp) transcription factors have high relevance in the signaling cascade associated with c-M...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.03.014

    authors: Basha R,Ingersoll SB,Sankpal UT,Ahmad S,Baker CH,Edwards JR,Holloway RW,Kaja S,Abdelrahim M

    更新日期:2011-07-01 00:00:00

  • Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).

    abstract:OBJECTIVE:To analyze the survival of women with malignant, mixed mullerian tumors of the ovary (OMMMT) compared to women with epithelial ovarian cancer (EOC). METHODS:Data from the Surveillance, Epidemiology and End Results (SEER) Program on 14025 women diagnosed with primary invasive ovarian cancer between 1988 and 1...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.02.016

    authors: Barnholtz-Sloan JS,Morris R,Malone JM Jr,Munkarah AR

    更新日期:2004-05-01 00:00:00